Search Results

You are looking at 71 - 80 of 254 items for :

Clear All
Open access

Emmanuelle Noirrit, Mélissa Buscato, Marion Dupuis, Bernard Payrastre, Coralie Fontaine, Jean-François Arnal and Marie-Cécile Valera

bone loss, vasomotor symptoms (hot flushes and sweats) and genito-urinary disturbances, affecting sexual function, relationships and quality of life. These symptoms are usually relieved by the administration of an estrogen. However, hormone replacement

Open access

Jeremy Turner, Neil Gittoes, Peter Selby and the Society for Endocrinology Clinical Committee

hypocalcaemia in these patients is available in the NKF KDOQI guidelines ( http://www2.kidney.org/professionals/KDOQI/guidelines_bone/Guide14.htm ) Vitamin D deficiency or hypomagnesaemia should be treated as described above Hazards of i.v. calcium

Open access

Jennifer Walsh, Neil Gittoes, Peter Selby and the Society for Endocrinology Clinical Committee

Introduction Under physiological conditions, serum calcium concentration is tightly regulated. Abnormalities of parathyroid function, bone resorption, renal calcium reabsorption or dihydroxylation of vitamin D may cause regulatory mechanisms

Open access

Shota Dzemaili, Jitske Tiemensma, Richard Quinton, Nelly Pitteloud, Diane Morin and Andrew A Dwyer

impact on mood, well-being, sex life and bone health. A Finnish cohort of 24 men and 9 women found patients with the longest gaps in treatment exhibited the most impaired bone density ( 39 ). Additionally, risk for osteopenia/osteoporosis may be further

Open access

Maria Mizamtsidi, Constantinos Nastos, George Mastorakos, Roberto Dina, Ioannis Vassiliou, Maria Gazouli and Fausto Palazzo

adenomas and hyperplasias ( 11 ). Normally, 99m Tc-sestamibi uptake is also observed in the thyroid, salivary glands, thymus, mammary gland during lactation, liver and bone marrow. This technique is sensitive (90%) and accurate (97.2%) for pHPT. There are

Open access

Peter D Mark, Mikkel Andreassen, Claus L Petersen, Andreas Kjaer and Jens Faber

. The symptoms in SH are vague, but adverse effects seem most prominent concerning the heart and the bones. Thus, SH increases bone loss by ∼50–100% in postmenopausal women due to increased bone turnover (1) . Concerning the heart, SH predisposes to the

Open access

Kranti Khadilkar, Vijaya Sarathi, Rajeev Kasaliwal, Reshma Pandit, Manjunath Goroshi, Gaurav Malhotra, Abhay Dalvi, Ganesh Bakshi, Anil Bhansali, Rajesh Rajput, Vyankatesh Shivane, Anurag Lila, Tushar Bandgar and Nalini S Shah

developed metachronous metastases after a median follow-up period of 17.5 months (range: 12–48 months). Synchronous metastases were common in bones, lungs and liver, whereas in patients with metachronous metastases, apart from bones, lungs and liver, five

Open access

Felix Haglund, Gustaf Rosin, Inga-Lena Nilsson, C Christofer Juhlin, Ylva Pernow, Sophie Norenstedt, Andrii Dinets, Catharina Larsson, Johan Hartman and Anders Höög

increased markers of bone metabolism (serum alkaline phosphatase, carboxy-terminal collagen or amino-terminal pro-peptide of type 1 collagen). Identification of single cells with strong ERB1 nuclear immunoreactivity in parathyroid tissue We initially

Open access

Kristin Godang, Karolina Lundstam, Charlotte Mollerup, Stine Lyngvi Fougner, Ylva Pernow, Jörgen Nordenström, Thord Rosén, Svante Jansson, Mikael Hellström, Jens Bollerslev, Ansgar Heck and the SIPH Study Group

, as previously described in detail ( 18 ). Key inclusion criteria were untreated mild PHPT, albumin-corrected serum calcium level between 2.60 and 2.80 mmol/L and age between 50 and 80 years. Key exclusion criteria were hyperparathyroid bone disease

Open access

Robert Rapaport, Peter A Lee, Judith L Ross, Paul Saenger, Vlady Ostrow and Giuseppe Piccoli

(eg, HSDS, age, insulin-like growth factor 1 (IGF-I) SDS) on changes in HSDS in response to GH therapy over time ( 12 , 13 ). The analysis described here evaluated growth outcomes (HSDS, IGF-I SDS and BMI SDS), bone age per chronological age (BA